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Abstract
Background: The obligate intracellular bacterial pathogen Coxiella burnetii causes the zoonosis Q
fever. The intracellular niche of C. burnetii has led to the assumption that cell-mediated immunity is
the most important immune component for protection against this pathogen. However, passive
immunization with immune serum can protect naïve animals from challenge with virulent C. burnetii,
indicating a role for antibody (Ab) in protection. The mechanism of this Ab-mediated protection is
unknown. Therefore, we conducted a study to determine whether Fc receptors (FcR) or
complement contribute to Ab-mediated immunity (AMI) to C. burnetii.
Results: Virulent C. burnetii infects and replicates within human dendritic cells (DC) without
inducing their maturation or activation. We investigated the effects of Ab opsonized C. burnetii on
human monocyte-derived and murine bone marrow-derived DC. Infection of DC with Ab-
opsonized C. burnetii resulted in increased expression of maturation markers and inflammatory
cytokine production. Bacteria that had been incubated with naïve serum had minimal effect on DC,
similar to virulent C. burnetii alone. The effect of Ab opsonized C. burnetii on DC was FcR dependent
as evidenced by a reduced response of DC from FcR knockout (FcR k/o) compared to C57Bl/6
(B6) mice. To address the potential role of FcR in Ab-mediated protection in vivo, we compared
the response of passively immunized FcR k/o mice to the B6 controls. Interestingly, we found that
FcR are not essential for AMI to C. burnetii in vivo. We subsequently examined the role of
complement in AMI by passively immunizing and challenging several different strains of
complement-deficient mice and found that AMI to C. burnetii is also complement-independent.
Conclusion: Despite our data showing FcR-dependent stimulation of DC in vitro, Ab-mediated
immunity to C. burnetii in vivo is FcR-independent. We also found that passive immunity to this
pathogen is independent of complement.
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Background
Coxiella burnetii is an obligate intracellular bacterium that
causes the zoonotic disease Q fever. Acute Q fever typi-
cally manifests as an incapacitating, flu-like illness with
symptoms including high-grade fever and periorbital
headache [1]. C. burnetii can persist in its host in a latent
state and may reactivate to cause chronic Q fever months
or years after initial exposure [2]. Historically, several dif-
ferent Q fever vaccines have been developed, the most
successful of which has been an Australian vaccine, Q-vax,
that consists of formalin inactivated C. burnetii [3]. One
dose of Q-vax provides long-lived protective immunity
[4]. However, this vaccine can cause severe side effects in
recipients with previous exposure to C. burnetii necessitat-
ing skin testing to determine the immune status of poten-
tial vaccinees prior to vaccination. Thus, there is a clear
need for a safe, effective subunit vaccine that eliminates
the need for pre-testing.
Despite the effectiveness of Q-vax, little is known about
the immune mechanisms responsible for the protective
immunity elicited by this vaccine. Due to the intracellular
niche of C. burnetii, it has long been thought that cell-
mediated immunity (CMI) must be required for protec-
tion against this pathogen. In support of this idea, Andoh
et al. [5] recently found T cells and interferon-γ are essen-
tial for resolution of a primary C. burnetii infection. While
CMI plays an important role in immunity to C. burnetii,
passive immunization studies, where serum from vacci-
nated animals is transferred into naïve animals, clearly
demonstrate that Ab alone is capable of providing com-
plete protection in an immunocompetent animal [6-10].
The development of potential subunit vaccine candidates
would benefit from a deeper understanding of the precise
mechanisms responsible for AMI to C. burnetii.
Antibody can provide protection against intracellular
pathogens via a number of different mechanisms. These
include direct bactericidal activity, complement activa-
tion, opsonization, cellular activation via Fc or comple-
ment receptors, and Ab-dependent cellular cytotoxicity
[11]. Here, we have examined the potential contributions
of FcR and complement in AMI to C. burnetii.
Results
Antibody opsonization does not affect C. burnetii viability 
or replication within phagocytic cells
Ab can mediate protective immunity against bacterial
pathogens through direct bactericidal effects or by activa-
tion of the complement cascade leading to membrane
attack complex deposition on the bacterial surface
[12,13]. There are published data showing that neither C.
burnetii-specific antibodies [14-16] nor complement [17]
are directly bactericidal towards virulent C. burnetii. To
confirm this, we determined whether Ab opsonization
affects replication in human macrophages (MΦ), an in
vitro model of C. burnetii infection [18]. We infected
human monocyte-derived MΦ with virulent phase I C.
burnetii that had been incubated with naïve human serum
or immune serum from a chronic Q fever patient contain-
ing high titers of anti-C. burnetii antibodies and measured
bacterial replication over 6 days by quantitative PCR.
While Ab opsonized bacteria were taken up more effi-
ciently by MΦ, there was little difference in bacterial yield
between Ab-opsonized and non-opsonized C. burnetii
with ~107 genome equivalents observed in each case 6
days post-infection (Fig. 1). We also tested the viability of
C. burnetii after incubation with specific Ab, complement
or both and observed no affect (data not shown). Taken
together, these data demonstrate that the traditional bac-
tericidal and opsonic mechanisms associated with Ab are
not likely to play significant roles in AMI to C. burnetii.
Antibody-opsonized C. burnetii stimulate human DC 
maturation and inflammatory cytokine production
Virulent phase I strains of C. burnetii that express full-
length LPS molecules infect and replicate within DC with-
out inducing DC maturation or inflammatory cytokine
production [19]. We hypothesized that Ab opsonization
of the bacteria would increase their ability to stimulate
DC. To test this, we infected human monocyte-derived
DC with phase I C. burnetii that had been incubated with
either naïve or immune human serum. Consistent with
our previous findings, infection with untreated control C.
burnetii did not result in DC maturation (Fig. 2) or inflam-
matory cytokine production (Fig. 3). Likewise, C. burnetii
that had been incubated with naïve human serum failed
to stimulate the DC. However, infection with C. burnetii
that had been incubated with immune serum resulted in
DC maturation and inflammatory cytokine production
similar to that observed after treatment of cells with E. coli
LPS (Fig. 2 and Fig. 3). Bacteria opsonized with heat-inac-
tivated immune serum stimulated equivalent DC matura-
tion and activation, indicating that complement was not
involved in this phenomenon (data not shown). Thus, Ab
opsonization of virulent C. burnetii dramatically increases
the response of DC to this pathogen.
Stimulation of mouse bone marrow-derived DC (BMDC) 
by Ab-opsonized C. burnetii is FcR-dependent
DC express multiple FcR on their surface and Ab-antigen
complexes can stimulate DC through their interactions
with a subset of these receptors [20]. We therefore exam-
ined the role of these receptors in stimulation of DC by
Ab-opsonized C. burnetii in vitro. FcR can be divided into
activating FcR and inhibitory FcR. The activating FcR asso-
ciate with a common γ-chain containing an immunore-
ceptor tyrosine-based activation motif [20]. To determine
the role of activating FcR in the response of DC to C. bur-
netii opsonized with mouse immune serum, we infectedBMC Immunology 2009, 10:26 http://www.biomedcentral.com/1471-2172/10/26
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BMDC from C57Bl/6 (WT) or a common gamma chain
knockout mouse strain (FcR k/o), and measured inflam-
matory cytokine production. Similar to what we observed
with human DC, WT mouse BMDC secreted increased
amounts of the inflammatory cytokines TNF and IL-6 in
response to Ab-opsonized C. burnetii (Fig. 4). However,
BMDC derived from FcR k/o mice showed greatly reduced
cytokine production in response to Ab-opsonized bacte-
ria. These data suggest that the effects of Ab-opsonized C.
burnetii on DC in vitro are FcR-dependent.
AMI to C. burnetii in vivo is FcR-independent
Because of the dramatic, FcR-dependent effect of Ab-
opsonized C. burnetii on DC in vitro, we wanted to deter-
mine the role of activating FcR in AMI to C. burnetii in
vivo. We used a mouse model of Q fever where mice are
challenged with 105 C. burnetii bacteria by the intraperito-
neal route [21]. Severity of infection was determined by
measuring increases in spleen weight and numbers of bac-
terial genome equivalents in the spleen at 2 weeks post-
infection. We tested the ability of Ab to protect WT or FcR
k/o mice by passively immunizing mice with mouse
immune or naïve serum 1 day prior to challenge. Interest-
ingly, WT and FcR k/o mice were equally protected by pas-
sive administration of immune serum. Both strains
showed a similar difference in spleen size and bacterial
genomes per spleen between naïve serum or immune
serum-treated mice (Fig. 5A and 5B). These data indicate
that FcR-dependent stimulation of DC, or any other FcR-
bearing cell type, is not essential for AMI to C. burnetii.
Role of complement in Ab-mediated immunity to C. 
burnetii
The complement system is important for AMI to a variety
of pathogens [22]. Ab-opsonized bacteria can activate the
complement cascade which can lead to clearance of result-
ant immune complexes. To examine the role of comple-
ment in AMI to C. burnetii, we passively immunized and
challenged several different complement-deficient mice.
We tested mice deficient in all three complement path-
ways, i.e., classical, alternative and lectin pathways, (C2/
factorB double knockout), the alternative and lectin path-
ways (Classical mouse, MBL/factorD double knockout),
the classical and lectin pathways (Alternative mouse,
MBL/C1q double knockout), and the classical and alter-
native pathways (Lectin mouse, C1q/factorD double
knockout). Among the immune serum treated animals,
we observed no statistical difference in spleen weight or
bacterial genome numbers per spleen between any of the
complement-deficient mouse strains and the WT mice
(Fig. 5A and 5B). We conclude from these data that AMI
to C. burnetii is complement-independent.
Discussion
Despite the obligate intracellular niche of C. burnetii, pas-
sive transfer of Ab to a naïve, immunocompetent animal
provides complete protection against challenge with this
pathogen. We sought to determine the specific immune
mechanisms responsible for Ab-mediated protection
against  C. burnetii. The fact that Ab alone can protect
against  C. burnetii challenge is even more intriguing
because this organism replicates within a phagolysosome-
like compartment of mononuclear phagocytes. Therefore,
the opsonic mechanisms that are traditionally thought to
target infectious organisms to phagocytes where they are
destroyed in phagolysosomes are not likely to play a role
in AMI to C. burnetii. In support of this, we show here that
Ab opsonization does not directly affect bacterial viability
or intracellular replication of C. burnetii in human MΦ.
Additionally, our passive immunization experiments with
FcR k/o mice indicate that traditional opsonic mecha-
nisms, which are typically FcR-dependent, are not essen-
tial for AMI to C. burnetii.
There are conflicting reports of the ability of Ab opsonized
C. burnetii to survive in phagocytes. Hinrichs and Jerrells
[15] found that immune serum opsonization of C. bur-
netii  increased bacterial uptake by guinea pig macro-
phages, but had no negative effect on the intracellular
replication of the organism. Likewise, Kazar et al. [16] and
Baca et al. [14] found that macrophages were unable to
control the growth of Ab-opsonsized C. burnetii. However,
a study published by another group showed that immune
serum opsonization allowed for increased uptake and
destruction of C. burnetii by guinea pig MΦ [23]. Our data
Growth of Ab-opsonized C. burnetii in human macrophages Figure 1
Growth of Ab-opsonized C. burnetii in human macro-
phages. C. burnetii (Cb) were incubated with naïve or 
immune human sera, washed and added to cultures of human 
monocyte-derived macrophages. Bacterial genome equiva-
lents in the culture were quantified at 0, 2, 4 and 6 days post-
infection by qPCR. The results shown are from one experi-
ment done in triplicate and representative of three independ-
ent experiments.
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show that human monocyte-derived macrophages do not
control growth of Ab-opsonized C. burnetii in vitro. In
interpreting these disparate results, it is important to keep
in mind that these are in vitro studies that may not accu-
rately reflect what is occurring in vivo. Further studies
involving histological analysis of the fate of Ab-opsonized
bacteria in vivo are clearly needed.
There have been several reports of protection of naïve ani-
mals from C. burnetii challenge by passive immunization
with immune serum. Interestingly, T cell deficient mice
are not protected by passive Ab transfer [9,10]. Thus,
whatever the mechanisms of AMI to C. burnetii may be,
they are dependent of the presence of T cells. DC express
FcR, are stimulated by immune complexes, and are potent
stimulators of naïve T cells. Therefore, we examined the
response of DC to Ab-opsonized C. burnetii and found
that DC are stimulated by Ab-opsonized C. burnetii in FcR-
dependent manner. This led us to examine the role of FcR
in AMI to C. burnetii in vivo. Given the results of our in
vitro experiments, we were surprised to find that AMI to C.
burnetii was totally independent of activating FcR. Thus,
Stimulation of human DC maturation by Ab-opsonized C. burnetii Figure 2
Stimulation of human DC maturation by Ab-opsonized C. burnetii. Human monocyte-derived DC were infected for 
24 h with C. burnetii (Cb), C. burnetii that had been incubated with naïve human serum (Cb + naïve), or C. burnetii that had been 
incubated with immune human serum (Cb + immune). Treatment of DC with E. coli LPS served as a positive control for matu-
ration. DC maturation was indicated by increased expression of the maturation markers CD86, CD80 and CD83 as deter-
mined by flow cytometry. Blue histograms represent untreated or uninfected control DC. Red histograms represent LPS 
treated or infected DC. Black histograms represent isotype controls. The mean fluorescence intensity (MFI) of untreated or 
uninfected DC and LPS-treated or infected DC are shown. The results shown are from one experiment and representative of 
three independent experiments.
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the FcR-dependent stimulation of DC, or any other cell
type, by Ab-opsonized bacteria is not essential for protec-
tion.
The common γ-chain FcR k/o mouse used in our studies
lacks expression of functional activating FcR. However,
these mice still express the inhibiting FcRIIb that can bind
immune complexes. It would be counterintuitive to
expect an inhibiting FcR to contribute to protective immu-
nity to a bacterial pathogen. However, there is one study
showing that both activating and inhibiting FcR need to
be knocked out in order to observe a defect in AMI to Bor-
detella bronchiseptica [24]. Thus, C. burnetii may be similar
in that both types of FcR need to be knocked out to see a
defect in AMI. Interestingly, AMI to B. bronchiseptica is also
dependent on a functional complement system [25],
which is not true for C. burnetii. Therefore, the mecha-
nisms involved in AMI to C. burnetii appear more complex
than what is known about AMI to other pathogens.
There are several possible mechanisms by which FcR-defi-
cient mice could be protected by passive administration of
Ab. Immune sera against bacterial pathogens like Neisseria
meningitidis  and  Borrelia burgdorferi are bactericidal
towards the organism [26,27]. For B. burgdorferi, Ab in
immune serum can be directly bactericidal whereas, in the
case of N. meningitidis, the bactericidal activity of immune
serum is dependent on a combination of Ab and comple-
ment. Our own data and those reported previously [14-
16] show that Coxiella-specific antibodies from immune
individuals or animals are not directly bactericidal.
Indeed, Ab enhances uptake of the bacteria by cells and
therefore promotes bacterial replication in vitro. There-
fore, Ab opsonization does not affect the replication of C.
burnetii. Furthermore, the combination of anti-Coxiella Ab
and complement does not affect bacterial viability and the
complement cascade is not essential for Ab-mediated pro-
tection in vivo.
There are several mechanisms by which complement can
contribute to AMI. The C1q component of the classical
complement pathway can recognize and bind to the Fc
portion of Ab leading to activation of the classical comple-
ment cascade and deposition of complement on the sur-
face of immune complexes. Mannose-binding lectin, a
component of the lectin pathway of complement activa-
tion, can also bind to the Fc portion of IgM [28]. The data
presented here demonstrate that none of the pathways of
complement activation play essential roles in AMI to C.
burnetii.
It is possible that in the absence of activating FcR, the
complement system can compensate and allow for pas-
sive protection of FcR-deficient animals and vice versa.
Thus, it would be interesting to examine passive immu-
nity in animals deficient in both FcR and complement.
Conclusion
The goal of this study was to determine the mechanism(s)
by which Ab contributes to immunity to C. burnetii. Inter-
estingly, despite our in vitro data indicating a potential
role for FcR, we were unable to define a mechanism of
AMI to C. burnetii in vivo. Thus, the role of Ab in protec-
tive immunity to this organism may be more complex
than what is seen with other pathogens and warrants fur-
ther investigation.
Methods
C. burnetii Purification and Antiserum Production
C. burnetii Nine Mile phase I (RSA493) was propagated in
African green monkey kidney (Vero) fibroblasts and puri-
fied by Renografin density gradient centrifugation [18].
Purified bacteria were suspended in K-36 buffer (0.1 M
KCl, 0.015 M NaCl, 0.05 M K2HPO4, 0.05 M KH2PO4, pH
7.0). Murine anti-Coxiella  antiserum was prepared by
immunizing C57Bl/6 mice i.p. three times at 2 wk inter-
vals with 108 fixed C. burnetii. C. burnetii were fixed with
4% paraformaldehyde for 24 h at 4°C. The bacteria were
washed three times with phosphate buffered saline (PBS,
Invitrogen, Carlsbad, CA) and resuspended in PBS at the
desired concentration. Immune sera were harvested 2 wks
after the final immunization and pooled. Serum from
unvaccinated mice was harvested as naïve (control)
serum. Human serum from a chronic Q fever patient was
Stimulation of human DC cytokine production by Ab- opsonized C. burnetii Figure 3
Stimulation of human DC cytokine production by 
Ab-opsonized C. burnetii. Human monocyte-derived DC 
were infected for 24 h with C. burnetii (Cb), C. burnetii that 
had been incubated with naïve human serum (Cb + naïve), or 
C. burnetii that had been incubated with immune human 
serum (Cb + immune). Treatment of DC with E. coli LPS 
served as a positive control for stimulation. The production 
of IL-1β, IL-6, IL12p70 and tumor necrosis factor (TNF) by 
human DC was determined by BioPlex multiplex cytokine 
assay. Levels below the limits of detection of the assay are 
indicated with an asterisk. The results shown are from one 
experiment and representative of three independent experi-
ments.
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generously provided by Ted Hackstadt, Rocky Mountain
Laboratories, NIAID, NIH.
Cell Culture
Human monocyte-derived DC were prepared as previ-
ously described [19]. Briefly, human PBMC were isolated
from buffy coats by centrifugation through a Ficoll-Paque
Plus (Amersham Pharmacia Biotech, Uppsala, Sweden)
density gradient. Cells were enriched for monocytes
(CD14+ cells) using a RossetteSep Monocyte Enrichment
Kit (Stem Cell Technologies, Vancouver, Canada). Mono-
cytes were resuspended at 106 cells per ml in DC medium
(RPMI +Glutamax [Invitrogen], 5% FBS, 15 mM Hepes,
0.1 mM non-essential amino acids, 1 mM sodium pyru-
vate, 100 U/ml penicillin and 100 μg/ml streptomycin)
containing IL-4 (10 ng/ml) and GM-CSF (10 ng/ml)
(Peprotech, Rocky Hill, NJ) and cultured for 6 days with
replacement of half of the medium and addition of fresh
cytokines every other day. Non-adherent DC were har-
vested by centrifugation and suspended in DC medium
without antibiotics. The resulting cells were determined to
be >95% CD11c+/CD209+ by flow cytometry. Monocyte-
derived macrophages were generated by culturing mono-
cytes in MΦ medium (RPMI, 10% FBS, and 50 ng/ml M-
CSF [Peprotech]) for 7 days. Adherent MΦ were harvested
by washing with cold PBS and gentle scraping.
The method used to prepare bone marrow derived DC
(BMDC) was adapted from methods described by Inaba et
al. [29]. Briefly, bone marrow cells were isolated from
C57Bl/6 or FcR k/o mouse femurs and cultured in DC
medium containing 20 ng/ml murine GM-CSF (Pepro-
tech) at 37°C, 5% CO2. After 3 days, the culture medium
and non-adherent cells were removed and replaced with
fresh DC medium containing fresh GM-CSF. The cells
were cultured with replacement of half of the medium
and addition of fresh cytokines every third day. After 6–8
days of culture, BMDC were harvested as non-adherent
cells. These cells were determined to be >80% CD11c+/
CD11b+ by flow cytometry.
For C. burnetii infection experiments, DC were plated in
24-well plates at a concentration of 5 × 105 per ml in DC
medium. Purified C. burnetii were added directly to the
culture medium at a multiplicity of infection (MOI) of
100. Unless otherwise indicated, the inoculum was not
removed. LPS from E. coli serotype O111:B4 (Sigma, St.
Louis, MO) was used at 500 ng/ml as a positive control for
DC stimulation/maturation. Cells were mock-infected
with K-36 buffer. For in vitro experiments in which C. bur-
netii were Ab opsonized, approximately 20 μl of a C. bur-
netii suspension (approximately 108 bacteria) were mixed
with 50 μl of naïve or immune serum (human or mouse)
and incubated for 30 min at room temperature. Bacteria
were washed twice with PBS (Invitrogen) and resus-
pended at the desired concentration in PBS.
Mouse Strains
C57Bl/6 and Fc receptor common gamma chain k/o
(Fcer1g) [30] mice on a C57Bl/6 background were
obtained from Taconic Farms (Germantown, NY). Breed-
ing colonies of C2/factorB double k/o [31] mice were
maintained at Taconic Farms. MBL/C1q double k/o, MBL/
factorD double k/o and C1q/factorD double k/o mice
were generated by interbreeding MBL k/o [32], C1q k/o
[33], and factorD k/o [34] mice and maintained at
Taconic Farms. All complement knockout mice were on
the C57Bl/6 background (backcrossed at least 10 genera-
tions).
Passive Immunization Experiments
On day -1, mice were injected with 300 μl naïve or
immune serum via the intraperitoneal (i.p.) route. On day
0, mice were challenged i.p. with 105 C. burnetii. Mice were
Response of C57Bl/6 and FcR k/o murine DC to Ab- opsonized C. burnetii Figure 4
Response of C57Bl/6 and FcR k/o murine DC to Ab-
opsonized C. burnetii. Bone marrow-derived dendritic 
cells were generated from B6 or FcR k/o mice. The cells 
were mock infected, or infected for 24 h with C. burnetii (Cb), 
C. burnetii that had been incubated with naïve mouse serum 
(Cb +naive) or C. burnetii that had been incubated with mouse 
immune serum (Cb +immune). Treatment of DC with E. coli 
LPS served as a positive control for stimulation. The concen-
trations of TNF and IL-6 in the DC supernatants were deter-
mined by BioPlex multiplex cytokine assay. Levels below the 
limits of detection of the assay are indicated with an asterisk. 
The results shown are from one experiment and are repre-
sentative of three independent experiments.
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sacrificed on day 14, spleens were harvested and blood
was collected. Severity of infection was determined by
measuring spleen weight and bacterial genomes per
spleen. All procedures and animal protocols used in this
study were approved by the Biosafety and IACUC com-
mittees at Rocky Mountain Laboratories. Work with viable
C. burnetii was conducted in either BSL-3 or ABSL-3 labo-
ratories.
Quantitative PCR
C. burnetii replication during infection of MΦ was quanti-
fied using TaqMan quantitative PCR (QPCR) of genome
equivalents as previously described [35]. Briefly, MΦ were
incubated with C. burnetii (MOI = 100) for 24 h at 37°C,
5% CO2. Non-adherent bacteria were removed by wash-
ing MΦ with Hank's balanced salt solution and the
medium replaced. This point was considered 0 h post-
infection. MΦ were harvested by scraping and DNA was
isolated with an UltraClean microbial DNA isolation kit
(MoBio Laboratories, Carlsbad, CA). For determination of
bacterial genome numbers in the spleen, a small portion
of spleen tissue (<50 mg) was excised from the spleen,
weighed, and DNA extracted using the same DNA isola-
tion kit. The primers/probe set used was designed with
PrimerExpress software (Applied Biosystems, Foster City,
CA) and is specific for the C. burnetii dotA gene. The for-
ward and reverse primers are GCGCAATACGCTCAAT-
CACA and CCATGGCCCCAATTCTCTT, respectively, and
the probe sequence is CCGGAGATACCGGCGGTGGG.
Purified plasmid DNA containing the C. burnetii dotA gene
was used as template to generate standard curves ranging
form 103 to 108 plasmid copies.
Flow Cytometry
Human DC were harvested by incubation for 5 min in
cold 0.1 M EDTA in PBS, followed by gentle scraping and
centrifugation at 500 × g for 5 min at 4°C. The following
monoclonal antibodies were used to characterize DC phe-
notypes: antiCD83-APC, antiCD86-PE, antiCD209-
PerCP-Cy5.5, antiCD80-FITC, and antiCD11c-PE (BD
PharMingen, San Diego, CA). Approximately 5 × 105 DC
were stained with antibodies in FACS Wash (PBS, 2% FBS)
for 15 min on ice, washed twice with FACS Wash and
fixed with 4% paraformaldehyde. Samples were run on a
FACS-Canto II flow cytometer (Becton Dickinson, San
Jose, CA) and analyzed using FlowJo software (TreeStar,
Ashland, OR).
Cytokine Assay
The concentrations of mouse IL-6 and TNF or human IL-
1β, IL-6, IL-12p70 and TNF in culture supernatants were
determined by BioPlex X-plex multiplex cytokine assay
(BioRad, Hercules, CA) according to the manufacturers
instructions.
Statistics
Statistical analysis was conducted to evaluate the signifi-
cance between differences. The Student's t-test was used to
compare the difference between groups. A p value of <0.05
was regarded as statistically significant.
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